Abstract Library

#4591 Efficacy of Trabectedin and Olaparib in homologous repair deficient neuroendocrine neoplasms – A subgroup analysis of the TOP-ART / PMO-1603 trial

Introduction: Genomic alterations resulting in homologous recombination deficiency (HRD) occur in a variety of cancers including neuroendocrine neoplasms (NEN). HRD-positive tumours are sensitive to PARP inhibitors such as olaparib. The DNA minor groove binder trabectedin leads to DNA double strand breaks and PARP activation. The combination of Trabectedin + Olaparib (TrO) may therefore have synergistic effects in HRD-positive tumours.

Conference:

Presenting Author: Apostolidis L

Authors: Apostolidis L, Ruebsam M, Teleanu M, Wagner S, Dorman K,

Keywords: Neuroendocrine Tumour, Neuroendocrine Carcinoma, targeted therapy, chemotherapy, HRD, olaparib, trabectedin, net, nec,

#4510 Follow-up analysis of group nutritional education in patients with neuroendocrine neoplasms (GEDNEN Course): A novel approach with proven acceptability

Introduction: Structured group education demonstrates improved outcomes in peri-operative health optimisation and diabetes mellitus. We devised and delivered a novel in person nutrition/dietary education programme for patients with neuroendocrine neoplasms (NENs) at the Sheffield ENETS Centre of Excellence.

Conference:

Presenting Author: Munir A

Authors: Wen Loh E, Walsh E, Bisson H, Ahmed Z, Dancyger-Stevens L,

Keywords: Group Education, Nutrition, Neuroendocrine Neoplasm, Novel Tool,

#4425 Ampullary composite gangliocytoma/neuroma and neuroendocrine tumour management

Introduction: Ampullary composite gangliocytoma/neuroma and neuroendocrine tumour (CoGNET), previously called ampullary gangliocytic paragangliomas (GP) are a rare entity, with only few reported cases in the literature.

Conference:

Presenting Author: Karam E

Authors: Karam E, Hollenbach M, Heise C, Abou Ali E, Gulla A,

Keywords: ampulla of Vater, gangliocytic paraganglioma, pancreaticoduodenectomy, transduodenal surgical ampullectomy, endoscopic papillectomy, composite gangliocytoma/neuroma neuroendocrine tumour, CoGNET,

#4374 Efficacy and safety of immunotherapy combined with antiangiogenesis agents and temozolomide in neuroendocrine carcinoma

Introduction: Platinum-based doublet chemotherapy is the standard first-line treatment, without standard treatment for second-line or subsequent systemic therapy for recurrent or progressive advanced neuroendocrine cancer (NEC).

Conference:

Presenting Author:

Authors: Li X, Yang M, Fan Q, Song L,

Keywords: Neuroendocrine carcinoma, Immunotherapy, Antiangiogenesis agents, Temozolomide,

#4356 Assessment of medium- and long-term side effects of Lu-177 treatment in patients with neuroendocrine tumours

Introduction: PRRT with Lu-177 has advanced the treatment of neuroendocrine tumours (NETs), adding a valuable tool against them. This study aims to assess its long-term impact, especially on the most radio-exposed organs—kidneys and bone marrow—and the reproducibility of in vivo clinical trial results (PFS).

Conference:

Presenting Author: Salcedo Cortes S

Authors: Salcedo Cortes S, Ardila Manjarés E, Mari Hualde A, Guzman Cruz A, Casallas Cepeda M,

Keywords: Neuroendocrine tumour (NET), [177Lu]Lu-DOTATATE, Long-term side effects, Radiosensitive organs, PFS,